Evidence map›Paper›PMID 39358991›Full record

ArticleRespirology (Carlton, Vic.)2025

Inflammation-induced loss of CFTR-expressing airway ionocytes in non-eosinophilic asthma.

Ling Chen, Gabriela A Hoefel, Prabuddha S Pathinayake, Andrew Reid, Amber L Pillar, Coady Kelly, HuiYing Tan, Ayesha Ali, Richard Y Kim, Philip M Hansbro and 7 more

Abstract read
In one paragraph

Article in Respirology (Carlton, Vic.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Contemporary Concise Review 2025: Asthma.Respirology (Carlton, Vic.) · 2026
    Review
  3. Article
  4. Review
  5. Pulmonary Ionocytes at the Crossroads of Absorption and Secretion: Clues from the Ferret.American journal of respiratory and critical care medicine · 2025
    Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Ling ChenSchool of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, New South Wales, Australia.
Gabriela A HoefelSchool of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, New South Wales, Australia.
Prabuddha S PathinayakeImmune Health Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia.ORCID 0000-0002-4947-5918
Andrew ReidImmune Health Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia.ORCID 0000-0001-5751-7025
Amber L PillarSchool of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, New South Wales, Australia.
Coady KellySchool of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, New South Wales, Australia.
HuiYing TanSchool of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, New South Wales, Australia.
Ayesha AliSchool of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, New South Wales, Australia.
Richard Y KimSchool of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, New South Wales, Australia.
Philip M HansbroSchool of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, New South Wales, Australia.
Steven L BrodyDepartment of Medicine, Washington University School of Medicine in St Louis, St Louis, Missouri, USA.
Paul S FosterSchool of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, New South Wales, Australia.
Jay C HorvatSchool of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, New South Wales, Australia.
Carlos RiverosImmune Health Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia.
Nikhil AwatadeImmune Health Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia.
Peter A B WarkImmune Health Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia.ORCID 0000-0001-5676-6126
Gerard E KaikoSchool of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, New South Wales, Australia.ORCID 0000-0002-3167-3174

Funding

National Health and Medical Research Council GNT1146524National Health and Medical Research Council GNT1162666National Health and Medical Research Council GNT1175134
6 · The paper itself

Abstract

BACKGROUND AND

objectiveSevere asthma is a heterogeneous disease with subtype classification according to dominant airway infiltrates, including eosinophilic (Type 2 high), or non-eosinophilic asthma. Non-eosinophilic asthma is further divided into paucigranulocytic or neutrophilic asthma characterized by elevated neutrophils, and mixed Type 1 and Type 17 cytokines in the airways. Severe non-eosinophilic asthma has few effective treatments and many patients do not qualify for biologic therapies. The cystic fibrosis transmembrane conductance regulator (CFTR) is dysregulated in multiple respiratory diseases including cystic fibrosis and chronic obstructive pulmonary disease and has proven a valuable therapeutic target. We hypothesized that the CFTR may also play a role in non-eosinophilic asthma.

methodsPatient-derived human bronchial epithelial cells (hBECs) were isolated and differentiated at the air-liquid interface. Single cell RNA-sequencing (scRNAseq) was used to identify epithelial cell subtypes and transcriptional activity. Ion transport was investigated with Ussing chambers and immunofluorescent quantification of ionocyte abundance in human airway epithelial cells and murine models of asthma.

resultsWe identified that hBECs from patients with non-eosinophilic asthma had reduced CFTR function, and did not differentiate into CFTR-expressing ionocytes compared to those from eosinophilic asthma or healthy donors. Similarly, ionocytes were also diminished in the airways of a murine model of neutrophilic-dominant but not eosinophilic asthma. Treatment of hBECs from healthy donors with a neutrophilic asthma-like inflammatory cytokine mixture led to a reduction in ionocytes.

conclusionInflammation-induced loss of CFTR-expressing ionocytes in airway cells from non-eosinophilic asthma may represent a key feature of disease pathogenesis and a novel drug target.

Indexed as

AsthmaCystic Fibrosis Transmembrane Conductance RegulatorEpithelial CellsAnimalsBronchiDisease Models, AnimalEosinophilsFemaleHumansInflammationMaleMiceNeutrophilsRespiratory MucosaCFTR protein, humanCystic Fibrosis Transmembrane Conductance Regulatorairway epitheliumCFTRionocytesmucousneutrophilssevere asthmasingle cell RNA‐sequencing

Identifiers

PMID39358991
PMCPMC11688627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.